Subverted macrophages in the triple-negative breast cancer ecosystem - 13/09/23

Abstract |
Tumor-associated macrophages (TAMs) are the most critical effector cells of innate immunity and the most abundant tumor-infiltrating immune cells. They play a key role in the clearance of apoptotic bodies, regulation of inflammation, and tissue repair to maintain homeostasis in vivo. With the progression of triple-negative breast cancer(TNBC), TAMs are "subverted" from tumor-promoting immune cells to tumor-promoting immune suppressor cells, which play a significant role in tumor development and are considered potential targets for cancer therapy. Here, we explored how macrophages, as the most important part of the TNBC ecosystem, are "subverted" to drive cancer evolution and the uniqueness of TAMs in TNBC progression and metastasis. Similarly, we discuss the rationale and available evidence for TAMs as potential targets for TNBC therapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | An exploration of how macrophages are gradually being "subverted" to drive cancer evolution. |
• | The uniqueness of TAMs in TNBC progression and metastasis was elucidated. |
• | The rationale and available evidence for TAMs as potential targets for TNBC treatment are detailed. |
• | The co-dependence of TAMs on tumor evolution was explored from the perspective of co-evolution of TAMs and TNBC ecosystem. |
• | It is helpful to optimize the current treatment plan of TNBC. |
Abbreviations : TAMs, TNBC, TME, M-CSF, HIF-1α, MARCO, TREM2, LPS, IFN-γ, TNF-α, iNOS, ROS, TGF-β, VEGF, CTL, Tregs, EMT, PIGF, TEMs, Ang2, MAMs, FOLFIRINOX, BPs, TLR, PAMP, DAMP, PI3Kγ, CAR-Ms, NP, CSC, RT, ICIs
Keywords : Tumor-associated macrophage, Triple-negative breast cancer, Target, Immunosuppression, Subvert
Plan
Vol 166
Article 115414- octobre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
